



Evofem Biosciences to Present at H.C. Wainwright BioConnect Conference

SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that the Company will present and host one-on-one meetings at the H.C. Wainwright BioConnect Virtual Conference being held from January 10 – 13, 2022.

Chief Executive Officer Sandra Pelletier will provide an update on the commercialization of Evofem's hormone-free contraceptive **Phexxi®** (lactic acid, citric acid and potassium bitartrate) as well as the Company's pipeline, including the **ongoing Phase 3 clinical trial** evaluating EVO100 for the prevention of chlamydia and gonorrhea in women and the recently announced **Multipurpose Prevention Technology (MPT) product candidate** for indications including the prevention of HIV in women.

The Company's presentation will be available for on demand listening beginning at 7:00am ET on Monday, January 10, 2022 through the H.C. Wainwright BioConnect conference portal and via <https://evofem.investorroom.com/HCWJan22> for 90 days.

To request a one-on-one meeting with Evofem during the conference, please contact your H.C. Wainwright representative or email ir@evofem.com.

About Evofem Biosciences

Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia, gonorrhea and HIV). The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evofem.com.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact

Amy Raskopf

Evofem Biosciences, Inc.

araskopf@evofem.com

Mobile: (917) 673-5775

SOURCE Evofem Biosciences, Inc.